These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

107 related items for PubMed ID: 33478856

  • 1. A novel TNIP2-RET fusion identified in a patient with mucinous adenocarcinoma of the lung.
    Ren P, Luo N, Qi Y, Wu Y, Jin M.
    Lung Cancer; 2021 Mar; 153():179-181. PubMed ID: 33478856
    [No Abstract] [Full Text] [Related]

  • 2. The clinical responses of TNIP2-ALK fusion variants to crizotinib in ALK-rearranged lung adenocarcinoma.
    Feng T, Chen Z, Gu J, Wang Y, Zhang J, Min L.
    Lung Cancer; 2019 Nov; 137():19-22. PubMed ID: 31521978
    [Abstract] [Full Text] [Related]

  • 3. KRAS Mutation for Staging Resected Non-Small Cell Lung Cancer.
    Canepa M, Patel NR, Griffith RC, Ng TT, Azzoli CG.
    J Thorac Oncol; 2019 Jul; 14(7):e153-e155. PubMed ID: 31235043
    [No Abstract] [Full Text] [Related]

  • 4. Identification of a Novel KIF5B-RET, ABHD17C-RET Double-Fusion Variant in Lung Adenocarcinoma and Response to Cabozantinib.
    Zheng Q, Fang W, Huang Y, Gan J, Zhang L.
    J Thorac Oncol; 2020 Aug; 15(8):e132-e133. PubMed ID: 32718536
    [No Abstract] [Full Text] [Related]

  • 5. WAC/RET: A Novel RET Oncogenic Fusion Variant in Non-Small Cell Lung Carcinoma.
    Velcheti V, Madison R, Ali SM, Schrock AB.
    J Thorac Oncol; 2018 Jul; 13(7):e122-e123. PubMed ID: 29935851
    [No Abstract] [Full Text] [Related]

  • 6. The KIF5B-RET Fusion Gene Mutation as a Novel Mechanism of Acquired EGFR Tyrosine Kinase Inhibitor Resistance in Lung Adenocarcinoma.
    Zhu YC, Wang WX, Zhang QX, Xu CW, Zhuang W, Du KQ, Chen G, Lv TF, Song Y.
    Clin Lung Cancer; 2019 Jan; 20(1):e73-e76. PubMed ID: 30366769
    [No Abstract] [Full Text] [Related]

  • 7. PARD3-ALK: A novel ALK fusion gene identified in a patient with lung adenocarcinoma.
    Yang L, Zhao W, Zhu H, Li X, Zhao G.
    Lung Cancer; 2021 Apr; 154():219-220. PubMed ID: 33676770
    [No Abstract] [Full Text] [Related]

  • 8. A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma.
    Hida T, Velcheti V, Reckamp KL, Nokihara H, Sachdev P, Kubota T, Nakada T, Dutcus CE, Ren M, Tamura T.
    Lung Cancer; 2019 Dec; 138():124-130. PubMed ID: 31710864
    [Abstract] [Full Text] [Related]

  • 9. Signet ring cell adenocarcinoma of the lung with an EML4-ALK fusion gene mimicking mucinous (colloid) adenocarcinoma: a case report.
    Ohba T, Sugio K, Kometani T, Yamaguchi M, Hamatake M, Nosaki K, Takeoka H, Kitajima H, Hirai F, Seto T, Taguchi K, Nishiyama K, Shida Y, Ichinose Y.
    Lung Cancer; 2011 Sep; 73(3):375-8. PubMed ID: 21719143
    [Abstract] [Full Text] [Related]

  • 10. Ciliated muconodular papillary tumour of the lung mimicking mucinous adenocarcinoma: a case report and literature review.
    Cheung FMF, Guan J, Luo QG, Sihoe ADL, Shen XP.
    Hong Kong Med J; 2019 Feb; 25(1):71-3. PubMed ID: 30713144
    [No Abstract] [Full Text] [Related]

  • 11. A Novel Intergenic LSM14A-RET Fusion Variant in a Patient With Lung Adenocarcinoma.
    Lv Y, Ling F, Zhang J, Xiao M, Mao W.
    J Thorac Oncol; 2020 Apr; 15(4):e52-e53. PubMed ID: 32216946
    [No Abstract] [Full Text] [Related]

  • 12. Identification of a novel crizotinib-sensitive MET-ATXN7L1 gene fusion variant in lung adenocarcinoma by next generation sequencing.
    Zhu YC, Wang WX, Xu CW, Zhang QX, Du KQ, Chen G, Lv TF, Song Y.
    Ann Oncol; 2018 Dec 01; 29(12):2392-2393. PubMed ID: 30339198
    [No Abstract] [Full Text] [Related]

  • 13. Small Cell Transformation in a Patient With RET Fusion-Positive Lung Adenocarcinoma on Pralsetinib.
    Dimou A, Lo YC, Merrell KW, Halling KC, Mansfield AS.
    JCO Precis Oncol; 2022 Dec 01; 6():e2200478. PubMed ID: 36542817
    [No Abstract] [Full Text] [Related]

  • 14. RET-Rearranged Lung Adenocarcinoma with Paraneoplastic Meige Syndrome.
    Abbar B, Henry C, Theou-Anton N, Brosseau S, Nguenang M, Pluvy J, Assoun S, Zalcman G, Gounant V.
    J Thorac Oncol; 2019 Nov 01; 14(11):e250-e251. PubMed ID: 31668323
    [No Abstract] [Full Text] [Related]

  • 15. Molecular characteristics of multifocal invasive mucinous adenocarcinoma of the lung: Report of a rare case.
    Tian Y, Zheng W, Ge H, Wang Y, Zha N, Huang S, Guo Z.
    Thorac Cancer; 2017 Nov 01; 8(6):710-713. PubMed ID: 28851076
    [Abstract] [Full Text] [Related]

  • 16. OFCC1-ALK (Ointergenic: A20): A novel OFCC1 intergenic region-ALK fusion identified from a lung adenocarcinoma patient.
    Zhai X, Wu Q, Zeng Z, Suo J, Lin F, Zhou Q.
    Lung Cancer; 2021 Mar 01; 153():171-173. PubMed ID: 33483163
    [No Abstract] [Full Text] [Related]

  • 17. Next-generation Sequencing Identified a Novel WDPCP-ALK Fusion Sensitive to Crizotinib in Lung Adenocarcinoma.
    He Z, Wu X, Ma S, Zhang C, Zhang Z, Wang S, Yu S, Wang Q.
    Clin Lung Cancer; 2019 Sep 01; 20(5):e548-e551. PubMed ID: 31281052
    [No Abstract] [Full Text] [Related]

  • 18. MPRIP-ALK, a Novel ALK Rearrangement That Responds to ALK Inhibition in NSCLC.
    Fang W, Gan J, Hong S, Lu F, Zhang L.
    J Thorac Oncol; 2019 Jul 01; 14(7):e148-e151. PubMed ID: 31235041
    [No Abstract] [Full Text] [Related]

  • 19. [Detection of ALK, ROS1 and RET fusion genes in non-small cell lung cancer patients and its clinicopathologic correlation].
    Zhong S, Zhang H, Bai D, Gao D, Zheng J, Ding Y.
    Zhonghua Bing Li Xue Za Zhi; 2015 Sep 01; 44(9):639-43. PubMed ID: 26705279
    [Abstract] [Full Text] [Related]

  • 20. Reply to "Emergence of High Level of MET Amplification During Treatment With Selpercatinib in KIF5B-RET NSCLC".
    Lin JJ, Solomon BJ.
    J Thorac Oncol; 2020 Jul 01; 15(7):e127-e128. PubMed ID: 32593454
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.